ClinicalTrials.gg
CompletedNCT02205424CANVASUpdated Jun 10, 2022

Cognition And Neocortical Volume After Stroke

An observational study in Ischaemic Stroke, Alzheimer's Disease and Vascular Dementia, sponsored by The Florey Institute of Neuroscience and Mental Health. Completed at 3 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-10.

Sponsored by The Florey Institute of Neuroscience and Mental Health · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
175
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Ischemic Stroke with a site in Australia — 17 open to participants now, 20 under way, 8 of them phase 3. Ischemic Stroke · Australia.

Started
2011
the only one that year
Observational
6 of 62
4 open now
Registered
12th of 62
by date
Lead sponsor
3 of 62
The Florey Institute of Neuroscience and Mental Health

Among the 62 studies in Ischemic Stroke with a site in Australia, this one is the only one that started in 2011, is one of 6 observational ones, and was the 12th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

17 of the 62 studies in Ischemic Stroke with a site in Australia are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Ischemic Stroke with a site in Australia, or all of them as a file.
02

Study summary

Stroke and dementia are two of the most common and disabling conditions worldwide, responsible for an enormous and growing burden of disease. There is increasing awareness that the two conditions are linked, with cognitive impairment and dementia common after stroke, vascular dementia accounting for about one-fifth of all dementia cases and recent evidence on the contribution of vascular risk factors to Alzheimer's disease. Yet little is known about whether brain volume loss - a hallmark of dementia - occurs after stroke, and whether such atrophy is related to cognitive decline. The aim of this research is to establish whether stroke patients have reductions in brain volume in the first three years post-stroke compared to control subjects, and whether regional and global brain volume change is associated with post-stroke dementia in order to elucidate potential causal mechanisms (including genetic markers, amyloid deposition and vascular risk factors). The hypotheses are that stroke patients will exhibit greater brain volume loss than comparable cohorts of stroke-free controls, and further, that stroke patients who develop dementia will exhibit greater global and regional brain volume loss than those who do not dement. An understanding of whether stroke is neurodegenerative, and in which patients, may be used to help guide the early delivery of disease-modifying therapies.

Read the detailed description

Our primary outcome measure was total brain volume (TBV) change between the 3-month and 3-year time-points compared between stroke patients and controls.

Secondary outcome 1 was TBV change between 3-months and 3-years comparing CN and CI stroke participants. TBV at 3-months will be adjusted for CCI scores, and years of education; the latter as it is correlated with cognitive performance and post-stroke dementia risk, but not for stroke lesion volume as no conclusive evidence for an effect has been demonstrated previously.

Secondary outcome 2 was hippocampal volume (HV) change between 3-months and 3-years in stroke patients and controls with adjustments identical to primary outcome.

Secondary outcome 3 was the comparison of HV change between 3-months and 3-years comparing CN and CI stroke participants with adjustments identical to secondary outcome 1.

See published protocol and uploaded statistical analysis plan for detailed description.

03

Conditions studied

  • Ischaemic Stroke
  • Alzheimer's Disease
  • Vascular Dementia

Keywords

  • Ischaemic stroke
  • Alzheimer's disease
  • Brain volume
  • Cortical thickness
  • Magnetic Resonance Imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Ischaemic stroke patients will have been admitted to the Acute Neurology Units of the Austin Hospital (Heidelberg), Royal Melbourne Hospital (Parkville), and Box Hill Hospital (Box Hill).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical stroke
  2. Aged greater than 18 years;
  3. Able to have cognitive testing and MRI scan; and
  4. Able to give

Exclusion criteria

Exclusion Criteria:

  1. Significant medical comorbidities precluding participation in cognitive testing, or making survival for three years unlikely;
  2. Normal exclusion criteria for MRI; e.g., implanted metal, severe claustrophobia;
  3. Pre-existing dementia
  4. Pregnancy, as a precaution to prevent exposing them to multiple MRI scans in a 12-month period
  5. People in existing dependent or unequal relationships with any member of the research team, to protect against coercion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
175 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Ischaemic stroke patients

    Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).

  • Healthy control participants

    People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.

06

What researchers measure

Primary outcomes

  1. Difference in total brain volume between 3 month and 3 year time-points

    We will examine changes in brain volume between the 3 month and 3 year time-points in ischemic stroke patients and healthy age-matched control participants

    Time frame: Between 3 months and 3 years post-stroke

Secondary outcomes

  1. Comparison of total brain volume (TBV) change between 3 month and 3 year time-points in those who were cognitively normal (CN) versus cognitively impaired (CI) determined at the 3 months post-stroke time point.

    Secondary outcome 1 was TBV change between 3-months and 3-years comparing CN and CI stroke participants.

    Time frame: Between 3 months and 3 years post-stroke

  2. Difference in hippocampal volume between 3 month and 3 year time-points in stroke and control participants.

    Secondary outcome 2 was hippocampal volume (HV) change between 3-months and 3-years in stroke patients and controls with adjustments identical to primary outcome.

    Time frame: Between 3 months and 3 years post-stroke

  3. Comparison of hippocampal volume change between 3 month and 3 year time-points in those who were cognitively normal versus cognitively impaired at 3 months post-stroke.

    Secondary outcome 3 was the comparison of HV change between 3-months and 3-years comparing CN and CI stroke participants with adjustments identical to secondary outcome 1.

    Time frame: Between 3 months and 3 years post-stroke

07

Study locations

3 sites
  • Eastern Health
    Box Hill, Victoria 3128, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Melbourne Health
    Parkville, Victoria 3050, Australia
08

References and documents

Publications

  • Hung SH, Khlif MS, Kramer S, Werden E, Bird LJ, Campbell BCV, Brodtmann A. Poststroke White Matter Hyperintensities and Physical Activity: A CANVAS Study Exploratory Analysis. Med Sci Sports Exerc. 2022 Sep 1;54(9):1401-1409. doi: 10.1249/MSS.0000000000002946. Epub 2022 Apr 25. PubMed 35482768 ↗
  • Brodtmann A, Werden E, Khlif MS, Bird LJ, Egorova N, Veldsman M, Pardoe H, Jackson G, Bradshaw J, Darby D, Cumming T, Churilov L, Donnan G. Neurodegeneration Over 3 Years Following Ischaemic Stroke: Findings From the Cognition and Neocortical Volume After Stroke Study. Front Neurol. 2021 Oct 22;12:754204. doi: 10.3389/fneur.2021.754204. eCollection 2021. PubMed 34744989 ↗
  • Brodtmann A, Khlif MS, Egorova N, Veldsman M, Bird LJ, Werden E. Dynamic Regional Brain Atrophy Rates in the First Year After Ischemic Stroke. Stroke. 2020 Sep;51(9):e183-e192. doi: 10.1161/STROKEAHA.120.030256. Epub 2020 Aug 10. PubMed 32772680 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Dec 2020, 115 months.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's 115 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2014
First posted
Jul 31, 2014
StartActual
May 1, 2011
Primary completionActual
Dec 31, 2020
CompletionActual
Jun 30, 2021
Last update
Jun 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02205424
Lead sponsor
The Florey Institute of Neuroscience and Mental Health
Collaborators
National Health and Medical Research Council, Australia
Responsible party
Amy Brodtmann (Prof Amy Brodtmann, The Florey Institute of Neuroscience and Mental Health) — Principal investigator
First posted
Jul 31, 2014
Start date
May 1, 2011
Primary completion
Dec 31, 2020
Completion
Jun 30, 2021
Last update
Jun 10, 2022

Study contacts

Amy G Brodtmann, MBBS PhD
principal investigator · The Florey Institute of Neuroscience and Mental Health

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion